Page 4 - Nasdaq Bcel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq bcel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Bcel Today - Breaking & Trending Today

Atreca (NASDAQ:BCEL) Downgraded by Zacks Investment Research

Atreca (NASDAQ:BCEL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range […] ....

Stifel Nicolaus , Tito Serafini , Atreca Inc , Goldman Sachs Group Inc , Zacks Investment Research , Renaissance Technologies , Hound Partners , De Shaw Co , Walleye Capital , Atreca Company Profile Get Rating , Get Rating , Goldman Sachs Group , Sachs Group , Company Profile , Nasdaq Bcel ,

Atreca, Inc. (NASDAQ:BCEL) Receives Consensus Recommendation of "Buy" from Brokerages

Atreca, Inc. (NASDAQ:BCEL – Get Rating) has been given a consensus rating of “Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages […] ....

Thomson Reuter , Stifel Nicolaus , Tito Serafini , Schonfeld Strategic Advisors , Atreca Inc , Gofen Glossberg , Stifel Financial Corp , Virtu Financial , Zacks Investment Research , Get Rating , Investment Research , Financial Corp , Nasdaq Bcel ,

Zacks: Analysts Anticipate Atreca, Inc. (NASDAQ:BCEL) Will Post Earnings of -$0.78 Per Share

Brokerages forecast that Atreca, Inc. (NASDAQ:BCEL – Get Rating) will report earnings per share of ($0.78) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atreca’s earnings, with estimates ranging from ($0.82) to ($0.72). Atreca posted earnings of ($0.70) per share in the same quarter last year, which would suggest a […] ....

United States , Thomson Reuter , Stifel Nicolaus , Tito Serafini , Atreca Inc , Morgan Stanley , Zacks Investment Research , America Corp , Parametric Portfolio Associates , Invesco Ltd , Get Rating , Portfolio Associates , Virginia Retirement Systems , Nasdaq Bcel ,

Atreca to Present at Upcoming Virtual Investor Conferences

SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing. ....

Canaccord Genuity , Rachel Ford Hutman , Alex Gray , Herb Cross , Atreca Inc , Exchange Commission , Annual Healthcare , Oncology Virtual , Gamma Deltat Cells , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Ford Hutman , Nasdaq Bcel ,

HC Wainwright Reaffirms "Buy" Rating for Atreca (NASDAQ:BCEL)

Atreca (NASDAQ:BCEL – Get Rating)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Wednesday, TipRanks reports. They presently have a $25.00 price target on the stock. A number of other brokerages have also issued reports on BCEL. Zacks Investment Research lowered shares of Atreca from a […] ....

United States , Stifel Nicolaus , Tito Serafini , Atreca Inc , Morgan Stanley , Zacks Investment Research , America Corp , Parametric Portfolio Associates , Invesco Ltd , Get Rating , Investment Research , Portfolio Associates , Virginia Retirement Systems , Nasdaq Bcel , Reiterated Rating , Hc Wainwright ,